ICLE on the Amgen/Horizon Therapeutics Settlement

FDA News – A recent ICLE amicus brief supporting the proposed merger between Amgen and Horizon Therapeutics was cited in an FDA News story about the companies’ settlement with the Federal Trade Commission. You can read full piece here.

Meanwhile, last week, Amgen and Horizon Therapeutics gained support from amicus briefs filed by PhRMA and the Biotechnology Innovation Organization (BIO) as well as from the International Center for Law Economics (ICLE), written with 11 scholars of antitrust law and economics from various universities.